Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 15, Number 10—October 2009

Research

Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy

Kevin L. WinthropComments to Author , Eric Chang, Shellie Yamashita, Michael F. Iademarco, and Philip A. LoBue
Author affiliations: Oregon Health and Sciences University, Portland, Oregon, USA (K.L. Winthrop, E. Chang, S. Yamashita); US Public Health Service, Washington, DC, USA (M.F. Iademarco); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (P.A. LoBue)

Main Article

Table 1

Reported diseases associated with anti–TNF-α therapy and therapy implicated for 105 cases of NTM disease, US Food and Drug Administration MedWatch database, 1999–2006*

Disease Infliximab Etanercept Adalimumab
Rheumatoid arthritis (n = 73) 51 17 5
Ankylosing spondylitis (n = 5) 1 3 1
Psoriasis (n = 4) 2 2 0
Crohn disease (n = 8) 8 0 0
Other (n = 15)† 11 3 1

*TNF-α, tumor necrosis factor-α; NTM, nontuberculous mycobacteria.
†Includes Wegener granulomatosis (n = 2), dermatomyositis (n = 1), uveitis (n = 1), juvenile rheumatoid arthritis (n = 1), and not reported (n = 10).

Main Article

TOP